Meeting
2015 ASCO Annual Meeting
A multi-center phase II study of high dose IL-2 (HD IL-2) sequenced with vemurafenib in patients with BRAF-V600E mutation positive advanced melanoma.
Authors
Joseph Clark
Loyola Univ Medical Center, Maywood, IL
Joseph Clark , Marc S. Ernstoff , Mohammed M. Milhem , Christopher D. Lao , David H. Lawson , Lawrence E. Flaherty , Theresa L. Luna , Sandra Aung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT01683188
Citation
J Clin Oncol 33, 2015 (suppl; abstr 9053)
DOI
10.1200/jco.2015.33.15_suppl.9053
Abstract #
9053
Poster Bd #
296
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
First-in-human clinical trial of an oncolytic adenovirus armed with TNFa and IL-2 in patients with advanced melanoma receiving adoptive cell transfer of tumor-infiltrating lymphocytes.
First Author: Inge Marie Svane
Poster
2024 ASCO Annual Meeting
Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients.
First Author: Rongsu Qi
Poster
2023 ASCO Annual Meeting
A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.
First Author: Daniel Olson
Poster
2023 ASCO Annual Meeting
OMNIA-1: A phase I/II study, an IL-2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti‑PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma.
First Author: Paolo Antonio Ascierto